News

Ossianix receives milestone payment from Lundbeck for blood-brain barrier (BBB) antibody delivery technology

Shark antibody technology has potential to deliver therapeutics across previously impermeable BBB 26 January 2017 – PHILADELPHIA, USA & STEVENAGE, UK: Ossianix Inc., which has generated a world leading platform for delivering biotherapeutic products into the CNS using the highly versatile single domain VNAR antibody from the shark, has received a milestone payment from Lundbeck following the successful completion of the objectives from a 2014 research collaboration agreement.  The project…

Read more

Ossianix presents at PEGS Europe 2016

Ossianix presents a poster “Combined in vivo/in vitro methods for selecting VNARs that shuttle large molecules across the blood brain barrier” and a talk “Delivery of CD20 (Rituximab)-Transferrin Receptor VNAR Bispecific Antibody to the Brain for Treatment of MS and Brain Cancer” at the Protein and Antibody Engineering Summit Europe 2016 in Lisbon. You can download poster here.

Read more

Ossianix publishes a research article

We published a research article in Molecular Immunology. Highlights: VNARs to BAFF with low nM potency were isolated from a semi-synthetic phage library. The CDR3 regions contain a conserved DXL motif found in all three BAFF receptors. VNARs to BAFF block B cell proliferation in response to either human or mouse BAFF. A chimeric VNAR-Fc fusion protein inhibited splenic B cell development in mice. To read more access it online here.…

Read more

OSSIANIX USES SHARK-DERIVED ANTIBODIES TO CROSS THE BBB

OSSIANIX USES SHARK-DERIVED ANTIBODIES TO CROSS THE BBB NeuroInsights 1st February 2016 Ossianix was founded in 2012 by Frank Walsh, Corey Goodman and Lynn Rutkowski, distinguished neuroscientists with extensive academic careers and senior level experience in the pharmaceutical industry. NeuroInsights caught up with Ossianix’s CEO Frank Walsh to discuss their innovative approach to crossing the blood-brain barrier. During Walsh’s tenure at Wyeth, it became apparent to him that biological approaches…

Read more